Form 4: Corcept Therapeutics Officer Sean Maduck Boosts Stake

Corcept Therapeutics' President of Endocrinology, Sean Maduck, reported recent acquisitions of common stock through a purchase plan and restricted stock awards, alongside a tax-related disposition.

Summary

• Sean Maduck, President of Corcept Endocrinology, acquired 454 shares of Corcept Therapeutics common stock on March 2, 2026, at a price of $35.97 per share, under a purchase plan.
• An additional 454 shares underlying unvested restricted stock awards were granted to Mr. Maduck on March 2, 2026, under the same purchase plan, with a price of $0.00.
• On March 3, 2026, 110 shares were disposed of by the Issuer to satisfy tax withholding obligations related to the vesting of restricted stock units, calculated at the closing price of $35.97 on March 2, 2026.
• Following these transactions, Mr. Maduck directly beneficially owns 8,977 shares of common stock.
• Indirect beneficial ownership includes 5,147 shares through the Sean and Molly Maduck Living Trust, 20,570 shares through MMM 2025, LLC, 40,000 shares through SNM 2025 Grantor Retained Annuity Trust, 34,000 shares through SNM 2026 Grantor Retained Annuity Trust, and 10,000 shares through Duckhill Capital, LLC (with beneficial ownership disclaimed except for pecuniary interest).
• The acquired restricted stock awards and previously granted unvested restricted stock awards (totaling 266, 888, 228, and 205 shares from various 2025 grants) are subject to 100% vesting on their one-year anniversary dates, contingent on satisfying certain requirements or maintaining beneficial ownership of Purchase Plan Shares.

Sentiment

Score: 6

Explanation: StockSavvy.ai views this filing as moderately positive. While the transactions are largely routine, the executive's acquisition of shares through a purchase plan and receipt of restricted stock awards generally indicates alignment with shareholder interests and confidence in the company's future.

Positives

• Sean Maduck's acquisition of 454 shares through a purchase plan indicates continued confidence in Corcept Therapeutics' future performance.
• The grant of 454 unvested restricted stock awards aligns management's interests with long-term shareholder value creation.

Negatives

• The disposition of 110 shares was for tax withholding purposes, a routine event, and does not reflect a voluntary sale by the insider.

Future Outlook

The filing does not contain specific forward-looking statements or guidance regarding the company's financial performance or strategic direction, focusing instead on individual executive stock transactions.

Management Comments

• The power of attorney under which this form was signed is on file with the Commission.

Industry Context

StockSavvy.ai notes that insider purchases, even routine ones like those under a 10b5-1 plan, can signal management's belief in the company's prospects within the pharmaceutical and biotechnology sector. This transaction is specific to an individual executive's compensation and investment strategy rather than a broader industry trend.

Related Party Transactions

• Indirect beneficial ownership is reported through various trusts and LLCs where the reporting person is a co-trustee, member, manager, or trustee, which are common structures for executive holdings.

Stakeholder Impact

• Shareholders may view the executive's stock acquisition as a positive signal of management confidence.
• Employees are not directly impacted by this specific insider transaction report.

Key Dates

Recommendation

This Form 4 filing details routine insider transactions, including stock acquisitions under a pre-arranged plan and tax-related dispositions. While the executive's purchase indicates confidence, the filing does not provide sufficient new information about the company's financial performance, strategic direction, or operational results to warrant a change from a 'hold' recommendation based solely on this disclosure. Investors should consider broader company fundamentals and market conditions.

Keywords

Corcept Therapeutics, CORT, Sean Maduck, Insider Trading, Form 4, Stock Acquisition, Restricted Stock Awards, Beneficial Ownership, Executive Compensation, Pharmaceuticals, Biotechnology